Quick Answer
Cue Biopharma, Inc. reported Long Term Debt of $0.00 for the year ending 2024.
- Cue Biopharma, Inc. showed a decrease of -100.0% in Long Term Debt from 2023 to 2024.
- This data is from Cue Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2021 to 2024 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $9.86 million | Q2 2022: $9.91 million | Q3 2022: $8.99 million | Q1 2023: $7.08 million | Q2 2023: $6.12 million | Q3 2023: $5.16 million | Q1 2024: $3.24 million | Q2 2024: $2.29 million | Q3 2024: $1.33 million.
- Historical annual values: Fiscal year 2024: $0.00 | Fiscal year 2023: $4.20 million | Fiscal year 2022: $8.04 million | Fiscal year 2021: $0.00.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: